Cargando…

Age-Related Macular Degeneration: What Do We Know So Far?

Ageing is a natural process that everyone experiences and nobody is an exception. With ageing, our body experiences physiological changes. In this article, the focus is made on the physiological changes of our eyes related to ageing and age-related macular degeneration (AMD), which is the most commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ho Hin, Liutkevičienė, Rasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Vilnius University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311835/
https://www.ncbi.nlm.nih.gov/pubmed/34393627
http://dx.doi.org/10.15388/Amed.2021.28.1.7
_version_ 1783729039367733248
author Ma, Ho Hin
Liutkevičienė, Rasa
author_facet Ma, Ho Hin
Liutkevičienė, Rasa
author_sort Ma, Ho Hin
collection PubMed
description Ageing is a natural process that everyone experiences and nobody is an exception. With ageing, our body experiences physiological changes. In this article, the focus is made on the physiological changes of our eyes related to ageing and age-related macular degeneration (AMD), which is the most common cause of incurable visual impairment in developed countries. With ageing populations increasing in many countries, more and more patients will have AMD in a foreseeable future. In Eastern Europe, blindness due to AMD, currently, is approximately 20% and there has been an increasing trend depicted in the future. Generally, AMD can be divided into early stages and two forms in an advanced (late) stage. Advanced AMD form includes neovascular AMD (wet) and geographic atrophy (late dry), both of these are associated with substantial, progressive visual impairment. The pathogenesis of AMD is complex and, by far, not completely understood. Multiple factors have been studied, for example: environmental factor, genetic factor (complement factor H), lifestyle. It has been proved that they are linked to higher the risk of developing of AMD, however, the actual pathogenesis is not yet formulated. AMD progression can also be a culprit to certain biochemical events and molecular changes linked to inflammation and pathological angiogenesis. In nowadays, we do have diagnostic methods for both early and late forms of AMD as well as ways to prevent progression of early AMD and wet AMD. However, until now, there is still no treatment for dry AMD. This article is a brief review of AMD and may hopefully lead to some future directions in early diagnostic methods and treating dry AMD.
format Online
Article
Text
id pubmed-8311835
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Vilnius University Press
record_format MEDLINE/PubMed
spelling pubmed-83118352021-08-13 Age-Related Macular Degeneration: What Do We Know So Far? Ma, Ho Hin Liutkevičienė, Rasa Acta Med Litu Review Papers Ageing is a natural process that everyone experiences and nobody is an exception. With ageing, our body experiences physiological changes. In this article, the focus is made on the physiological changes of our eyes related to ageing and age-related macular degeneration (AMD), which is the most common cause of incurable visual impairment in developed countries. With ageing populations increasing in many countries, more and more patients will have AMD in a foreseeable future. In Eastern Europe, blindness due to AMD, currently, is approximately 20% and there has been an increasing trend depicted in the future. Generally, AMD can be divided into early stages and two forms in an advanced (late) stage. Advanced AMD form includes neovascular AMD (wet) and geographic atrophy (late dry), both of these are associated with substantial, progressive visual impairment. The pathogenesis of AMD is complex and, by far, not completely understood. Multiple factors have been studied, for example: environmental factor, genetic factor (complement factor H), lifestyle. It has been proved that they are linked to higher the risk of developing of AMD, however, the actual pathogenesis is not yet formulated. AMD progression can also be a culprit to certain biochemical events and molecular changes linked to inflammation and pathological angiogenesis. In nowadays, we do have diagnostic methods for both early and late forms of AMD as well as ways to prevent progression of early AMD and wet AMD. However, until now, there is still no treatment for dry AMD. This article is a brief review of AMD and may hopefully lead to some future directions in early diagnostic methods and treating dry AMD. Vilnius University Press 2021 2021-01-18 /pmc/articles/PMC8311835/ /pubmed/34393627 http://dx.doi.org/10.15388/Amed.2021.28.1.7 Text en Copyright © 2021 Ho Hin Ma, Rasa Liutkevičienė. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review Papers
Ma, Ho Hin
Liutkevičienė, Rasa
Age-Related Macular Degeneration: What Do We Know So Far?
title Age-Related Macular Degeneration: What Do We Know So Far?
title_full Age-Related Macular Degeneration: What Do We Know So Far?
title_fullStr Age-Related Macular Degeneration: What Do We Know So Far?
title_full_unstemmed Age-Related Macular Degeneration: What Do We Know So Far?
title_short Age-Related Macular Degeneration: What Do We Know So Far?
title_sort age-related macular degeneration: what do we know so far?
topic Review Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311835/
https://www.ncbi.nlm.nih.gov/pubmed/34393627
http://dx.doi.org/10.15388/Amed.2021.28.1.7
work_keys_str_mv AT mahohin agerelatedmaculardegenerationwhatdoweknowsofar
AT liutkevicienerasa agerelatedmaculardegenerationwhatdoweknowsofar